SYRS News and Press, Syros Pharmaceuticals Inc. From 08/08/22

Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has ...

Clinical-stage biotech Syros Pharmaceuticals ( NASDAQ: SYRS ) on Wednesday that the European Medicines Agency (EMA) issued a positive opinion for an orphan drug designation for its lead asset tamibarotene in myelodysplastic syndrome (MDS). The shares of micro-cap biotech sur...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan drug designation for tamibarotene for the...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and pro...

Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...

Development stage biotech firms Syros Pharmaceuticals ( SYRS ) and Tyme Technologies ( NASDAQ: TYME ) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros ( SYRS ) will acquire Tyme ( TYME ). Tyme ( TYME )...

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial o...

Syros Pharmaceuticals, Inc. (SYRS) Q1 2022 Earnings Conference Call May 16, 2022, 08:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and IR Nancy Simonian - CEO Jason Haas - CFO David Roth - Chief Medical Officer Kristin Stephens - Chief Development Office E...

Syros Pharmaceuticals press release (NASDAQ:SYRS): Q1 GAAP EPS of -$0.40 beats by $0.07. Revenue of $5.47M (+13.3% Y/Y) beats by $0.55M. Cash, cash equivalents and marketable securities as of March 31, 2022 were $112.9 million, as compared with $143.4 million on December 31, 2021. Syros belie...

Three Data Readouts Expected in 2022: Data from the Safety Lead-ins of the SY-5609 Trial in Pancreatic Cancer and of the SELECT-AML-1 Phase 2 Trial; Data from the Dose Confirmation Study of SY-2101 in APL On Track to Report Data from Ongoing SELECT-MDS-1 Pivotal Trial ...